Form 4: Adaptive Biotechnologies Exec Sells Shares

Harlan S. Robins, Chief Scientific Officer at Adaptive Biotechnologies Corp, reported the sale of company stock totaling over 386,000 shares.

Summary

• Harlan S. Robins, Chief Scientific Officer of Adaptive Biotechnologies Corporation, executed transactions involving the sale of common stock.
• These sales occurred on July 2, 2026, and were conducted under a Rule 10b5-1 trading plan adopted on March 13, 2026.
• A total of 239,351 shares were sold at a weighted-average price of $21.74, and an additional 146,889 shares were sold at a weighted-average price of $22.45.
• Following these transactions, Robins beneficially owns 1,166,547 shares directly.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a slightly negative sentiment due to the significant sale of shares by a key executive, despite the transaction being conducted under a pre-arranged trading plan.

Negatives

• The Chief Scientific Officer sold a significant number of shares, totaling over 386,000.

Future Outlook

No forward-looking statements or guidance are present in this filing.

Industry Context

StockSavvy.ai notes that insider selling, particularly by a Chief Scientific Officer, can sometimes be interpreted by the market as a signal of reduced confidence, although the use of a Rule 10b5-1 plan suggests these sales were pre-planned and not necessarily based on new, non-public information.

Stakeholder Impact

• Shareholders may view the significant sale of stock by the Chief Scientific Officer with concern, potentially impacting share price in the short term.

Key Dates

Recommendation

The filing indicates a significant sale of stock by a key executive, which could be a short-term negative signal. However, the sale was executed under a Rule 10b5-1 plan, suggesting it was pre-determined and not necessarily a reflection of current negative insights. Without further financial or strategic information, a 'hold' recommendation is prudent, advising investors to monitor future company performance and executive trading activity.

Keywords

Adaptive Biotechnologies Corp, ADPT, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Harlan S. Robins, Chief Scientific Officer